Healthcare / Pharmaceutical RetailersTokyo
$518.00
+3.00 (+0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.4B · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15.1B
P/E
14.1x
↓EV/EBITDA
5.7x
↓ROE
7.8%
↑Gross Margin
41.5%
↓Debt/Equity
1.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.7%
FCF CAGR
-10.0%
FCF margin
1.1%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $122.39B · net income $1.26B · FCF $1.37B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $122.39B | $122.39B | $115.36B | $109.55B | $106.69B |
| Net Income | $1.26B | $1.26B | $1.86B | $1.61B | $2.39B |
| EBITDA | $6.42B | $6.42B | $6.90B | $6.25B | $7.05B |
| EPS | 43.20 | 43.20 | 61.89 | 53.38 | 79.35 |
| Gross Margin | 41.5% | 41.5% | 41.5% | 41.9% | 41.6% |
| Operating Margin | 2.6% | 2.6% | 3.3% | 2.9% | 3.6% |
| Net Margin | 1.0% | 1.0% | 1.6% | 1.5% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.83 | 1.83 | 1.92 | 2.11 | 2.23 |
| Current Ratio | 0.92 | 0.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.37B | $1.37B | $5.62B | $3.37B | $1.88B |
| Returns | |||||
| ROE | 7.8% | 7.8% | 12.3% | 11.1% | 18.0% |
| Valuation | |||||
| P/E | 14.13 | 14.13 | 10.32 | 7.46 | 6.63 |
| EV/EBITDA | 5.68 | 5.68 | 5.81 | 5.50 | 5.28 |
| P/B | 0.93 | 0.93 | 1.27 | 0.83 | 1.20 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 5.3% | 2.7% | — |
| EPS Growth | -30.2% | -30.2% | 15.9% | -32.7% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.1%
EPS terminal req.
$45.96
Spread vs growth
-32.3%
5Y implied EPS CAGR
5.2%
EPS terminal req.
$55.62
Spread vs growth
-35.4%
10Y implied EPS CAGR
7.6%
EPS terminal req.
$89.57
Spread vs growth
-37.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.2%
Start / end P/E
7.0x → 11.9x
EPS bridge
61.89 → 43.20
Residual
-20.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.